Peripheral leukocytes with HLA-DR+/CD8- phenotype are associated with prognosis in patients with lung cancer

Anticancer Res. 2003 Sep-Oct;23(5b):4149-52.

Abstract

Background: We have previously reported that the most significant immunological prognostic factors in patients with lung cancer are the percentages of peripheral HLA-DR+ lymphocytes.

Patients and methods: We performed two-color flow cytometric analyses using two combinations of double-staining to identify lymphocyte phenotypes HLA-DR/CD4 and HLA-DR/CD8, and examined the correlation between the expression of these subsets and survival in 51 patients with non-small cell lung cancer.

Results: The percentages of HLA-DR+, HLA-DR+/CD4+ (activated helper/inducer T cells) and HLA-DR+/CD8+ (activated cytotoxic/suppressor T cells) did not correlate with survival. However, survival was better when the percentage of HLA-DR+/CD8- was below normal (p = 0.0267). The 4-year survival rate in patients with high and low percentages of peripheral HLA-DR+/CD8- lymphocytes was 26.0% and 53.2%, respectively.

Conclusion: The subset of HLA-DR+/CD8- lymphocytes powerfully predicts the survival of patients with non-small cell lung cancer.

MeSH terms

  • Carcinoma, Non-Small-Cell Lung / blood
  • Carcinoma, Non-Small-Cell Lung / immunology*
  • Female
  • Flow Cytometry
  • HLA-DR Antigens / immunology*
  • Humans
  • Immunophenotyping
  • Lung Neoplasms / blood
  • Lung Neoplasms / immunology*
  • Male
  • Prognosis
  • Survival Rate
  • T-Lymphocyte Subsets / immunology
  • T-Lymphocytes, Cytotoxic / immunology*
  • T-Lymphocytes, Helper-Inducer / immunology
  • T-Lymphocytes, Regulatory / immunology*

Substances

  • HLA-DR Antigens